Table 1 The demographic and clinical characteristics of the patients enrolled in this study.
From: High-throughput 3D microvessel-on-a-chip model to study defective angiogenesis in systemic sclerosis
Patient | Age (years) Sex | Disease duration (years) | Digital ulcers | PAH | Capillaroscopic pattern | ANA-ENA | Drug treatment |
|---|---|---|---|---|---|---|---|
71 dSSc | 52 F | 10 | Yes | No | Active | Antinucleolar-Scl-70 | lloprost, Bosentan, glucocorticoids |
72 ISSc | 34 F | 1.5 | No | No | Active | Antinucleolar-Scl-70 | Glucocorticoids |
74 ISSc | 42 F | 0.5 | No | No | Active | Antinucleolar-Scl-70 | Nifedipine |
75 dSSc | 61 F | 10 | No | No | Active | Antinucleolar-Scl-70 | lloprost, glucocorticoids, MMF |
77 ssSSc | 70 F | 10 | Yes | Yes | Active | Antinucleolar-Scl-70 | lloprost, Bosentan, Nifedipine |
79 dSSc | 71 F | 10 | Yes | Yes | Active-late | Antinucleolar-Scl-70 | Macitentan, MMF, Nifedipine |
SO dSSc | 67 F | 1 | No | Yes | Active | Antinucleolar-Scl-70 | Macitentan, MMF, glucocorticoids |
83 ISSc | 58 F | 4 | No | No | Active | Antinucleolar-Scl-70 | Glucocorticoids, Nifedipine, Azathioprine |
Mean (SD) | 56.9 (13.4) | 5.9 (4.5) |
